The Native Antigen Company (part of LGC Clinical Diagnostics) has launched its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.
The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.
In February and September of each year, the World Health Organization (WHO) announces flu vaccine formulations for the northern and southern hemispheres.
To support vaccine research and development, The Native Antigen Company has developed Haemagglutinin and Neuraminidase antigens for the WHO-recommended, egg-based and recombinant vaccine strains.
The latest range of antigens can be used in immunoassay development and as immunogens, and includes reagents for both influenza A and B.
Ish Jalal, Commercial Director, The Native Antigen Company, said: “Each year, we are proud to be able to support vaccine and diagnostic manufacturers by updating our range of influenza reagents in line with WHO’s guidance.”
